Kinetic Suppression of Microtubule Dynamic Instability by Griseofulvin: Implications for Its Possible Use in the Treatment of Cancer

Total Page:16

File Type:pdf, Size:1020Kb

Kinetic Suppression of Microtubule Dynamic Instability by Griseofulvin: Implications for Its Possible Use in the Treatment of Cancer Kinetic suppression of microtubule dynamic instability by griseofulvin: Implications for its possible use in the treatment of cancer Dulal Panda*†, K. Rathinasamy*, Manas K. Santra*, and Leslie Wilson†‡ *School of Biosciences and Bioengineering, Indian Institute of Technology, Bombay 400076, India; and ‡Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, CA 93106 Edited by John A. Carbon, University of California, Santa Barbara, CA, and approved May 19, 2005 (received for review March 5, 2005) The antifungal drug griseofulvin inhibits mitosis strongly in fungal caused by the impairment of the organization or function of cells and weakly in mammalian cells by affecting mitotic spindle the spindle MTs rather than their depolymerization. Griseo- microtubule (MT) function. Griseofulvin also blocks cell-cycle pro- fulvin is able to bind weakly to mammalian-brain tubulin and gression at G2͞M and induces apoptosis in human tumor cell lines. to inhibit the polymerization of MTs in vitro; however, inhi- Despite extensive study, the mechanism by which the drug inhibits bition of brain tubulin polymerization requires very high mitosis in human cells remains unclear. Here, we analyzed the concentrations of griseofulvin (5, 7). ability of griseofulvin to inhibit cell proliferation and mitosis and MTs exhibit two forms of nonequilibrium dynamics, tread- to affect MT polymerization and organization in HeLa cells to- milling and dynamic instability (3). Most of the earlier work on gether with its ability to affect MT polymerization and dynamic griseofulvin was carried out before the realization that mitotic instability in vitro. Griseofulvin inhibited cell-cycle progression at spindle MTs are highly dynamic, and that the rapid dynamics of prometaphase͞anaphase of mitosis in parallel with its ability to the MTs, not just their presence, are critical for proper spindle function (3, 8–13). Further, most antimitotic MT-targeted drugs inhibit cell proliferation. At its mitotic IC50 of 20 ␮M, spindles in blocked cells displayed nearly normal quantities of MTs and MT that act on animal cells suppress MT dynamics at concentrations organization similar to spindles blocked by more powerful MT- that often are far below the concentrations required to inhibit targeted drugs. Similar to previously published data, we found (e.g., the vinca alkaloids) (9) or increase (e.g., paclitaxel) (10, 11) that very high concentrations of griseofulvin (>100 ␮M) were MT polymerization. Further, several antimitotic drugs that weakly inhibit MT polymerization in cells and in vitro, including required to inhibit MT polymerization in vitro. However, much noscapine (12), estramustine (13), and benomyl (14), suppress lower drug concentrations (1–20 ␮M) strongly suppressed the MT dynamic instability and treadmilling remarkably strongly in dynamic instability behavior of the MTs. We suggest that the the absence of appreciable inhibition of polymerization. primary mechanism by which griseofulvin inhibits mitosis in hu- In pursuing the earlier results of Grisham et al. (4), we man cells is by suppressing spindle MT dynamics in a manner reasoned that, like the aforementioned drugs, griseofulvin might qualitatively similar to that of much more powerful antimitotic inhibit proliferation and mitosis in human cancer cells primarily drugs, including the vinca alkaloids and the taxanes. In view of by suppressing MT dynamics. Thus, we analyzed the ability of griseofulvin’s lack of significant toxicity in humans, we further griseofulvin to inhibit the polymerization of brain tubulin into suggest that it could be useful as an adjuvant in combination with MTs and its ability to modulate MT dynamic instability in vitro more powerful drugs for the treatment of cancer. together with its ability to inhibit cell proliferation and mitosis and to affect MT organization in HeLa cells. We found that cancer chemotherapy ͉ mitosis griseofulvin inhibited mitosis in parallel with its ability to inhibit cell proliferation, and that at its IC50 for inhibition of mitosis (20 riseofulvin, an orally active nontoxic antifungal antimitotic ␮M), the organization of the MTs in the blocked spindles Gdrug derived from several species of Penicillium (1), has appeared nearly normal. In addition, griseofulvin bound weakly been used for many years for the treatment of Tinea capitis to tubulin, and inhibition of MT polymerization in vitro required Ͼ ␮ (ringworm) and other dermatophyte infections (2). Its mecha- griseofulvin concentrations 100 M. In contrast, griseofulvin nism of action has been thought to involve the selective inhibi- suppressed the dynamic instability of the MTs remarkably Ͻ ␮ tion of fungal cell mitosis in association with its accumulation in strongly (IC50 for overall dynamicity, 1 M). Our data strongly the keratin layers of the epidermis (1). Early studies demon- support the hypothesis that inhibition of mitosis in human cancer strated that griseofulvin inhibits mitosis in sensitive fungi in a cells is due to the suppression of spindle MT dynamics. A recent manner resembling the actions of colchicine and other antimi- report indicates that griseofulvin either alone or in combination with nocodazole inhibits tumor production in athymic mice (15). totic drugs that act in mammalian cells by disrupting spindle Taking these observations together with the data described in microtubule (MT) function (3), although its precise mechanism this work, we suggest that griseofulvin might be useful in of action in sensitive fungi remains unclear. The antiproliferative combination with more powerful MT-targeted drugs or with and antimitotic effects of griseofulvin in mammalian cells are agents acting on novel targets for the treatment of cancer. very weak, with inhibition requiring high micromolar concen- trations (4, 5). Materials and Methods The question of whether inhibition of mitosis by griseofulvin Reagents. Griseofulvin, GTP, EGTA, colchicine, piperazine-1,4- involves MT depolymerization or some other action on MTs in bis(2-ethanesulfonic acid) (Pipes), and Mes were purchased human cells has remained unsettled. Specifically, griseofulvin clearly inhibits MT polymerization coincident with inhibition of mitosis in echinoderm eggs (6), and inhibition of mitosis at This paper was submitted directly (Track II) to the PNAS office. high griseofulvin concentrations in 3T3 cells occurs together Abbreviations: MT, microtubule; MAP, MT-associated protein; Pipes, piperazine-1,4-bis(2- with depolymerization of the spindle MTs (5). In contrast, ethanesulfonic acid). inhibition of mitosis by griseofulvin in HeLa cells occurred in †To whom correspondence may be addressed. E-mail: [email protected] or wilson@ the absence of significant spindle MT depolymerization (4), lifesci.ucsb.edu. which was interpreted as indicating that mitotic inhibition was © 2005 by The National Academy of Sciences of the USA 9878–9883 ͉ PNAS ͉ July 12, 2005 ͉ vol. 102 ͉ no. 28 www.pnas.org͞cgi͞doi͞10.1073͞pnas.0501821102 Downloaded by guest on October 1, 2021 from Sigma. Phosphocellulose (P11) was obtained from What- Immunofluorescence microscopy was performed as described man. All other chemicals used were of analytical grade. in ref. 14. The cells were seeded on poly(L-lysine)-coated cov- erslips at a density of 1 ϫ 105 cells per ml contained in 24-well Purification of Goat and Bovine Brain Tubulins. Goat brain MT tissue culture plates. After 40 h of drug treatment, cells were protein, tubulin plus MT-associated proteins (MAPs), was iso- fixed in 3.7% formaldehyde for 30 min at 37°C and then treated lated as described in refs. 14 and 16. Bovine MT protein was with cold 100% methanol (Ϫ20°C) for 20 min. After the obtained as described in ref. 17. Goat and bovine tubulin were nonspecific sites had been blocked with 2% BSA͞PBS, the cells separated from the MAPs by using phosphocellulose chromatog- were incubated with mouse monoclonal anti-␣-tubulin antibody raphy and stored at Ϫ80°C. The tubulin concentration was deter- (Sigma) at 1:300 dilution for 2 h at 37°C. Coverslips were then mined by the Bradford method using BSA as the standard (18). rinsed with BSA͞PBS and incubated with anti-mouse IgG antibody labeled with Alexa Fluor 568 (Molecular Probes) at The Effects of Griseofulvin on Glutamate-Induced MT Polymerization 1:100 dilution for1hat37°C. Coverslips were then rinsed with in Vitro. Goat brain tubulin (11 ␮M) was polymerized for 30 min PBS and incubated with DAPI (1 ␮g͞ml) for 20 s. The MTs and at 37°C in 25 mM Pipes buffer, pH 6.8, containing 1 M sodium DNA were observed with an Eclipse TE-2000 U microscope glutamate, 1 mM GTP, and 5 mM MgCl2 in the absence or (Nikon). The images were analyzed by using IMAGEPRO PLUS presence of griseofulvin. The polymerized MTs were sedimented software (Media Cybernetics, Silver Spring, MD). by centrifugation (52,000 ϫ g for 40 min), and the MT polymer Mitotic indices were determined by Wright–Giemsa staining mass was determined. Samples for transmission electron micros- (14). Briefly, the cells were plated at a density of 5 ϫ 104 cells copy were prepared as described in ref. 14, and MT structures per ml in 24-well plates 24 h before the addition of griseofulvin. were observed with a Tecnai G212 electron microscope (FEI, The cells were then treated with different concentrations of The Netherlands) at ϫ43,000 magnification. griseofulvin and incubated for an additional 20 or 40 h. Both the attached and unattached cells were harvested and combined Effects of Griseofulvin on Seeded MT Assembly. MT nucleating seeds after trypsinization (0.025% trypsin, 10 min), washed with PBS, were constructed by polymerizing goat brain tubulin (3.5 mg͞ml) and then treated with 0.5ϫ PBS for 10 min on ice. The cells were in the presence of 6 M glycerol and 1 mM GTP at 37°C for 45 fixed with methanol͞acetic acid solution (3:1, vol͞vol). Finally, min and shearing the MTs into small fragments by repeated the cell suspensions were spread onto cold slides, air-dried, and passage through a 25-gauge needle. For measurement of poly- stained with a 10% Giemsa solution.
Recommended publications
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies
    molecules Article Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies Pradeep Kumar Bolla 1 , Carlos A. Meraz 1, Victor A. Rodriguez 1, Isaac Deaguero 1, Mahima Singh 2 , Venkata Kashyap Yellepeddi 3,4 and Jwala Renukuntla 5,* 1 Department of Biomedical Engineering, College of Engineering, The University of Texas at El Paso, 500 W University Ave, El Paso, TX 79968, USA 2 Department of Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA 3 Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT 84112, USA 4 Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA 5 Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27240, USA * Correspondence: [email protected] Received: 9 August 2019; Accepted: 28 August 2019; Published: 29 August 2019 Abstract: Global incidence of superficial fungal infections caused by dermatophytes is high and affects around 40 million people. It is the fourth most common cause of infection. Clotrimazole, a broad spectrum imidazole antifungal agent is widely used to treat fungal infections. Conventional topical formulations of clotrimazole are intended to treat infections by effective penetration of drugs into the stratum corneum. However, drawbacks such as poor dermal bioavailability, poor penetration, and variable drug levels limit the efficiency. The present study aims to load clotrimazole into ufosomes and evaluate its topical bioavailability. Clotrimazole loaded ufosomes were prepared using cholesterol and sodium oleate by thin film hydration technique and evaluated for size, polydispersity index, and entrapment efficiency to obtain optimized formulation.
    [Show full text]
  • Producing In-Situ Nanoparticles of Griseofulvin Using Supercritical Antisolvent Methodology
    University of Rhode Island DigitalCommons@URI Open Access Dissertations 2013 Producing In-Situ Nanoparticles of Griseofulvin using Supercritical Antisolvent Methodology Pratik Sheth University of Rhode Island, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Sheth, Pratik, "Producing In-Situ Nanoparticles of Griseofulvin using Supercritical Antisolvent Methodology" (2013). Open Access Dissertations. Paper 25. https://digitalcommons.uri.edu/oa_diss/25 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. PRODUCING IN-SITU NANOPARTICLES OF GRISEOFULVIN USING SUPERCRITICAL ANTISOLVENT METHODOLOGY BY PRATIK SHETH A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN BIOMEDICAL AND PHARMACEUTICAL SCIENCES UNIVERSITY OF RHODE ISLAND 2013 DOCTOR OF PHILOSOPHY DISSERTATION OF PRATIK SHETH APPROVED: Dissertation Committee: Major Professor M. Serpil Kislalioglu Ph.D David Worthen Ph.D. Michael L. Greenfield Ph.D Nasser H. Zawia Ph.D DEAN OF THE GRADUATE SCHOOL UNIVERSITY OF RHODE ISLAND 2013 ABSTRACT Poor aqueous solubility of drug candidates is a major challenge for the pharmaceutical scientists involved in drug development. Particle size reduction to nano scale appears as an effective and versatile option for
    [Show full text]
  • UTROGESTAN 100Mg Capsules Progesterone
    NEW ZEALAND DATA SHEET UTROGESTAN 100mg capsules Progesterone 1 PRODUCT NAME UTROGESTAN 100MG CAPSULES 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Soft, round, slightly yellow capsule containing a whitish oily suspension of 100 mg progesterone (micronised). Excipient(s) with known effect: Soya lecithin For full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Capsules, soft 4 CLINICAL PARTICULARS 4.1 Therapeutic indications UTROGESTAN 100 mg capsule is indicated in adults, via the oral route, for: Hormone replacement therapy • Adjunctive use with an oestrogen in postmenopausal women with an intact uterus (for hormone replacement therapy [HRT]) 4.2 Dose and method of administration Dosage The recommended dose is as follows, according to the indication: Oral Route • In the treatment of menopause: oestrogen alone therapy is not recommended on its own in menopausal women with an intact uterus. The usual dose is 200 mg/day at bedtime at least 12 to 14 days per month, i.e. on days 15 to 26 of each cycle or in the last 2 weeks of each treatment sequence of oestrogen therapyfollowed by approximately one week without any replacement therapy and during which withdrawal bleeding may occur. Alternatively 100 mg can be given at bedtime, from days 1 to 25 of each cycle, withdrawal bleeding being less with this treatment schedule. Method of Administration This product is intended only for oral use. UTROGESTAN 100 mg should not be taken with food; it is preferable to take the capsules in the evening at bedtime. UTROGESTAN 100mg caps UTROGEST005 Jan 2018 Page 1 of 9 NEW ZEALAND DATA SHEET Oral Route Each capsule of UTROGESTAN 100 mg must be swallowed with a little water.
    [Show full text]
  • Divestra Leaflet
    • Known or suspected estrogen-dependent neoplasia Drugs which may decrease the therapeutic effect of Cyproterone acetate+Ethinyl Pregnancy and Breastfeeding • Undiagnosed abnormal vaginal bleeding Combination of Cyproterone acetate and Ethinyl estradiol is contraindicated during estradiol and increase the incidence of breakthrough bleeding • Any ocular lesion arising from ophthalmic vascular disease, such as partial or complete pregnancy and breastfeeding. loss of vision or defect in visual fields Effects on ability to drive and use machines • Concomitant use with other Estrogen+Progestogen combinations or estrogens or Unknown progestogens alone • When pregnancy is suspected or diagnosed Adverse Reactions • Severe diabetes with vascular changes Common adverse reactions includes headaches, nausea, abdominal pain, weight gain, • A history of otosclerosis with deterioration during pregnancy depressed or altered mood and breast pain or tenderness. • Hypersensitivity to this drug or to any ingredient in the formulation or component of the Uncommon adverse reactions include vomiting, diarrhea, fluid retention and migraine. container. Overdose (Cyproterone acetate + Warnings and Precautions There is no antidote and treatment should be symptomatic. Ethinyl estradiol) Discontinue Cyproterone acetate+Ethinyl estradiol tablets at the earliest manifestation of the following: PHARMACOLOGICAL PROPERTIES • Thromboembolic and Cardiovascular Disorders such as thrombophlebitis, pulmonary Pharmacotherapeutic group: Sex hormones and modulators of the genital system, QUALITATIVE AND QUANTITATIVE COMPOSITION embolism, cerebrovascular disorders, myocardial ischemia, mesenteric thrombosis, and anti-androgens and estrogens. ATC code: G03HB01 Each film-coated tablet contains: retinal thrombosis. Cyproterone acetate (Ph.Eur.)………...2 mg • Conditions that predispose to Venous Stasis and to Vascular Thrombosis (eg. Mechanism of action Ethinyl estradiol (USP)……………...0.035 mg immobilization after accidents or confinement to bed during long-term illness).
    [Show full text]
  • Emerging Threat in Antifungal Resistance on Superficial Dermatophyte Infection R Sultana1, M Wahiduzzaman2
    Bang Med J Khulna 2018; 51 : 21-24 ORIGINAL ARTICLE Emerging threat in antifungal resistance on superficial dermatophyte infection R Sultana1, M Wahiduzzaman2 Abstract Background: Dermatophytosis are most common fungul infection globally and according to WHO the prevalence is about 20-25% and does not spare people of any race or age. Over the past few years antifungal resistance has been emerged due to irrational use of antifungal drugs in cutaneous mycosis. Objective: The aim of the study is to evaluate the efficacy of different antifungul drugs (Terbinafin. Fluconazole, Itraconazole, Griseofulvin) on superficial mycosis depending on various factors. Methods: This prospective study was conducted among the Superficial fungul infected patients from April' 2017 to October 2017 in Khulna Medical College Hospital (KMCH) and dermatologist's private chamber in Khulna city. All the enrolled patients were put on oral Terbinafin, Fluconazole, Itraconazole and Griseofulvin. Each patient was given single antifungal drug orally. These cases were thus followed up after two months of treatment to look for persistent infection, cure or any relapse clinically. Result: Among 194 patient 89 were given Tab. Terbinafin (250mg) where resistance cases were 20.22%. More cases (33.96%) were resistant to Cap. Fluconazol (50mg). High percentage of cases were resistant to Cap. Itraconazole (76.47%). Griseofulvin resistant cases were observed in 25.71%. Drug response is very poor (69%) in patient who had been suffering from diabetes mellitus. Conclusion: Appropriate antifungal drugs should be chosen with strict indication, dose, duration, selection of perfect local preparation and taking laboratory facilities where necessary. Keywords : Dermatophytosis, Antifungal resistance, Public health.
    [Show full text]
  • Adverse Effects of Medications on Oral Health
    Adverse Effects of Medications on Oral Health Dr. James Krebs, BS Pharm, MS, PharmD Director of Experiential Education College of Pharmacy, University of New England Presented by: Rachel Foster PharmD Candidate, Class of 2014 University of New England October 2013 Objectives • Describe the pathophysiology of various medication-related oral reactions • Recognize the signs and symptoms associated with medication-related oral reactions • Identify the populations associated with various offending agents • Compare the treatment options for medication-related oral reactions Medication-related Oral Reactions • Stomatitis • Oral Candidiasis • Burning mouth • Gingival hyperplasia syndrome • Alterations in • Glossitis salivation • Erythema • Alterations in taste Multiforme • Halitosis • Oral pigmentation • Angioedema • Tooth discoloration • Black hairy tongue Medication-related Stomatitis • Clinical presentation – Aphthous-like ulcers, mucositis, fixed-drug eruption, lichen planus1,2 – Open sores in the mouth • Tongue, gum line, buccal membrane – Patient complaint of soreness or burning http://www.virtualmedicalcentre.com/diseases/oral-mucositis-om/92 0 http://www.virtualmedicalcentre.com/diseases/oral-mucositis-om/920 Medication-related Stomatitis • Offending agents1,2 Medication Indication Patient Population Aspirin •Heart health • >18 years old •Pain reliever • Cardiac patients NSAIDs (i.e. Ibuprofen, •Headache General population naproxen) •Pain reliever •Fever reducer Chemotherapy (i.e. •Breast cancer •Oncology patients methotrexate, 5FU, •Colon
    [Show full text]
  • Read All of This Leaflet Carefully Before You Start Using This Medicine
    PACKAGE LEAFLET: INFORMATION FOR THE USER Progesterone Besins® 100mg Capsules, soft progesterone Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Progesterone Besins is and what it is used for 2. What you need to know before you take Progesterone Besins 3. How to take Progesterone Besins 4. Possible side effects 5. How to store Progesterone Besins 6. Contents of the pack and other information 1. What Progesterone Besins is and what it is used for The name of your medicine is Progesterone Besins 100mg Capsules, soft (called Progesterone Besins in this leaflet). Progesterone Besins contains a female hormone called progesterone and is to be used with another medicine called estrogen. The combination of Progesterone Besins and estrogen belongs to a group of medicines called hormone replacement therapy (HRT). What Progesterone Besins is used for Progesterone Besins in combination with an estrogen is used to reduce the symptoms of the menopause (change of life). It is used only in women who still have a womb (uterus).
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Marine Mammal Pharmacology
    27 PHARMACEUTICALS AND FORMULARIES CLAIRE A. SIMEONE AND MICHAEL K. STOSKOPF Contents Introduction Introduction .......................................................................... 593 This chapter aims to provide clinicians and scientists working Routes for Administering Drugs to Marine Mammals ......... 594 with marine mammals with a convenient and rapidly acces- Dose Scaling ......................................................................... 595 sible single source on the subject. A compilation of the avail- Drug Interactions and Adverse Effects ................................ 596 able pharmacological information on cetaceans, pinnipeds, Life-Threatening Adverse Reactions .................................... 596 sirenians, sea otters (Enhydra lutris), and polar bears (Ursus Hepatic Effects ...................................................................... 596 maritimus) is provided. Readers must be aware at all times Renal Effects ......................................................................... 597 that drugs discussed in this chapter may have only been Gastrointestinal Effects ......................................................... 597 used on a limited number of individual animals from a nar- Nervous System Effects ........................................................ 597 row range of species, so all information must be interpreted Dermal Effects ...................................................................... 598 with caution. No drugs have been licensed for use in marine Otic Effects ...........................................................................
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • FDA Briefing Document Pharmacy Compounding Advisory Committee
    FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting June 23, 2016 The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the Pharmacy Compounding Advisory Committee (advisory committee). We are bringing certain compounding issues to this advisory committee to obtain the committee’s advice. The background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. The FDA does not intend to issue a final determination on the issues at hand until input from the advisory committee process has been considered, all reviews have been finalized, consultation with the United States Pharmacopeia has occurred, and public comment has been considered through notice and comment rulemaking. The final determination may be affected by issues not discussed at the advisory committee meeting. Table of Contents I. Introduction ................................................................................................................... 3 A. Bulk Drug Substances That Can Be Used by Compounders under
    [Show full text]